Novo Nordisk’s Pivotal Week: Guidance and Competition in Focus

Novo Nordisk DK0062498333

All eyes are on Novo Nordisk this week as the pharmaceutical giant prepares to release its annual results. The report, however, is expected to be about much more than a review of the past year. Investors are keenly awaiting management's outlook for 2026 and early signals on the U.S. launch trajectory of its new Wegovy pill, set against a backdrop of intensifying competition in the obesity drug market.

According to the company's calendar, Novo Nordisk will publish financial figures for the fourth quarter and full year 2025 on February 4, 2026, prior to the market open in Copenhagen. A conference call for analysts and investors is scheduled to follow from 1:00 p.m. to 2:00 p.m. Central European Time.

The timing of this update is particularly sensitive. The past year presented Novo Nordisk with significant headwinds, including mounting competitive pressure from Eli Lilly and increasing pricing challenges in the crucial U.S. market. Consequently, the market consensus is that the corporate guidance for fiscal year 2026 will be the central focus of the event, offering a crucial indicator of the company's resilience.

Early Momentum for Wegovy's Oral Formulation

Entering this critical period, the company has received some positive news. Data from IQVIA, cited by Reuters and shared with analysts on January 30, indicates a robust initial uptake for the Wegovy pill in the United States. In its second full week following the commercial launch, new prescriptions surpassed 26,000. This follows over 18,000 in the first full week and an initial 3,071 in the first four days after the January 5 launch. Analysts at Barclays characterized the debut as "very strong" in the Reuters report.

This launch is strategically significant as it represents the first GLP‑1 pill approved for weight loss in the U.S., providing a distinct advantage in a therapeutic area historically dominated by injectable treatments.

The commercial strategy appears equally assertive. Reports indicate the company set introductory cash prices between $149 and $299 per month, varying by dosage strength. Furthermore, the product's availability through major pharmacy chains and telehealth providers is anticipated to accelerate patient access significantly.

A Competitive Landscape That Is Expanding Rapidly

While Eli Lilly remains the primary rival, with its Mounjaro and Zepbound products gaining market share against Novo's semaglutide-based therapies, the competitive field is broadening. Eli Lilly itself is advancing its own oral candidate, orforglipron, through the FDA review process with a decision expected in 2026.

The competition extends beyond this core rivalry. In a clear signal of the sector's attractiveness, AstraZeneca finalized a licensing deal worth up to $18.5 billion in late January to access weight-loss drugs from China's CSPC. Additional oral GLP‑1 development programs are being actively pursued by other players, including Pfizer, Structure Therapeutics, and Viking Therapeutics.

For Novo Nordisk, the narrative in 2026 will therefore hinge not merely on sustained demand but on the company's ability to defend its market share and pricing power. The early performance of the Wegovy pill will be a key factor in mitigating these broader market pressures.

Recent Share Performance: Despite a year-to-date gain of over 9%, the company's shares have declined by approximately 9.5% over the past seven trading days, according to the provided data.

Looking Ahead on the Calendar: Following the February 4 earnings report, the next major corporate event is the Annual General Meeting scheduled for March 26, 2026. The subsequent first-quarter results for 2026 are due for release on May 6, 2026.